Red Eyes in Renal Failure

Berlyne, G.M.; Shaw, A.B.

doi:10.1016/s0140-6736(67)92418-x

Cited by 112 publications

(40 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conjunctival and comeal calcifications are frequent and generally asympto matic [3][4][5][6][7][8][9]. Conjunctival irritation due to calcium deposits in the most superficial layer is possible and is known as 'red eyes of renal failure' [3,6,7]. Conjunctival hemorrhages are sometimes seen in HD patients and are also generally asymptomatic [3,10].…”

Section: Discussionmentioning

confidence: 99%

Intraocular Pressure in Chronic Renal Failure Patients Treated with Maintenance Hemodialysis

Hojs

Pahor²

1997

Ophthalmologica

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Intraocular Pressure in Chronic Renal Failure Patients Treated with Maintenance Hemodialysis

Hojs

Pahor²

1997

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Dis turbances of divalent ion and phosphorus metabolism may cause hyperpara thyroidism, osteomalacia, metastatic soft tissue calcification resulting in enor mous unsightly masses growing out of the pelvis or shoulder girdle, metastatic calcific deposits in arteries which can be troublesome in subsequent arterio venous fistula surgery for haemodialysis treatment [Mallick. and Berlyne, 1969], corneal and conjunctival calcification giving rise to 'red eyes' or white painless eyes [Berlyne and Shaw, 1967;Berlyne, 1969] and, in cases with extreme hypocalcaemia, blindness from metabolic cataracts [Berlyne et al, 1971].…”

Section: Discussionmentioning

confidence: 99%

Rarity of Renal Osteodystrophy in Israel due to Low Phosphorus Intake

Berlyne¹,

Ben-Arie²,

Epstein³

et al. 1973

Nephron

Self Cite

View full text Add to dashboard Cite

Renal osteodystrophy is very rare in undialysed chronic renal failure in Israel, and common in Western Europe and North America. In a dietary survey it was found that there was a lower dietary phosphorus intake in Israel (942 ± 23.1 mg/ day) compared to a mean of 1,238 ± 65.0 mg/day in the UK in healthy subjects on their normal diet, whereas the daily intake of calcium was higher in Israel (1,071 ± 58.5 mg/day) compared to 887 ± 33.5 mg/day in the UK. In an investigation of non-dialysed chronic renal failure patients in Israel it was found that at all levels of renal failure in Israel plasma phosphate levels were lower than in a personal series from England and that plasma calcium levels were more frequently lower than in the UK or USA series. The plasma Ca × P product was below 70 in all cases in Israel. The data were interpreted as indicating that a lower P load in Israel resulting from a lower protein intake results in a lower plasma phosphate level at all levels of renal failure and so the development of hyperparathyroidism is delayed until a very late stage of renal failure. The results are compatible with the Bricker ‘trade-off’ hypothesis suggesting that a reduction of phosphorus intake daily in renal disease may prevent the development of renal osteodystrophy.

show abstract

“…A 'red eye' [2], which was developed in 3 cases on Ix-OH-Ds in the 3rd month of the study, disappeared within a few weeks after discontinuing the administration of the drug. None of these 3 patients had experienced a 'red eye' before.…”

Section: Resultsmentioning

confidence: 99%

“…In this context, there is some evidence that the intestinal absorption of phosphorus may be augmented by la-OH -D3 [12,22], Thus la-OH-Da treatment may lead to increase in serum phosphorus as well as serum calcium. Virtually, with a daily dose of 2 tag of I a-OH-Da, a typical 'red eye' [2] developed in 3 of 5 patients on 1 a-OH-D.a who had a calcium-phosphorus product of more than 70 at the 3rd month of the study, so that the calcium-phos phorus product should be carefully monitored to avoid ectopic calcification. A randomized double-blind study by Maxwell et al [18] showed a decrease in serum alkaline phosphatase after an 11-week treatment with 1,25-(OH)2-D3.…”

Section: Discussionmentioning

confidence: 99%

1-Year Controlled Trial of 1α-Hydroxycholecalciferol in Patients on Maintenance Hemodialysis

Shimamatsu¹,

Maeda²,

Harada³

et al. 1981

Nephron

View full text Add to dashboard Cite

A 1-year controlled trial was performed to confirm the effects of 1α-hydroxycholecalciferol (1α-OH-D₃) in chronic hemodialysis patients. Initially, a daily dose of 2 µg of 1α-OH-D₃ was given orally to 24 patients and its placebo to another 24 patients during the first 3 months. For the following 9 months the dose of 1α-OH-D₃ or its placebo was reduced to 1 µg per day in the individual groups. Serum calcium was significantly increased to the normal level after 1 month of treatment and sustained at this level for 1 year. Serum parathyroid hormone was significantly decreased at 3 months. Serum alkaline phosphatase was decreased to the normal level at the 5th month and thereafter. At 2 months serum phosphorus was significantly increased in the 1α-OH-D₃ group. None of the patients on 1α-OH-D₃ showed increased subperiosteal resorption on X-rays, whereas 8 out of 20 patients on placebo did (p < 0.002). No adverse effects were seen apart from 3 patients with the ‘red eye’ of scleral calcification.

show abstract

Red Eyes in Renal Failure

Cited by 112 publications

References 4 publications

Intraocular Pressure in Chronic Renal Failure Patients Treated with Maintenance Hemodialysis

Intraocular Pressure in Chronic Renal Failure Patients Treated with Maintenance Hemodialysis

Rarity of Renal Osteodystrophy in Israel due to Low Phosphorus Intake

1-Year Controlled Trial of 1α-Hydroxycholecalciferol in Patients on Maintenance Hemodialysis

Contact Info

Product

Resources

About